Coronary Flow Reserve Changes After Semaglutide Treatment

NCT07190144 | Completed

• 1 other identifier: IstanbulU-EBKaraayvaz-2
• Study Type: observational
• Target: 122
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this observational study is to learn about the effects of semaglutide to coronary artery flow in diabetic and non-diabetic patients. The main question it aims to answer is: Does semaglutide enhance coronary artery flow in diabetic and non-diabetic patients? Participants already planned taking semaglutide by an endocrine specialist as their treatment was assessed with CFR before and 3 months after.

Conditions

The Study Focused on the Vascular Effects of Semaglutide in Both Diabetic and Non-diabetic Patients; Obesity &Amp; Overweight

Keywords

Coronary Flow Reserve; Semaglutide; Diabetes Mellitus

Outcome Measures

Primary Outcomes (1)

• Number of patients who had acute coronary syndrome

  Semaglutide is known for its beneficial effects on coronary vasculature. If a patient had myocardial infarction, this patient can no longer participate in study because the CFR ultimately changes.

  From start of the study to 3 months after

Secondary Outcomes (1)

• Number of patients who can not lose weight

  From start to 3 months

Study Arms (2)

Non-diabetic patients

Non-diabetic patients who have planned to given semaglutide by an endocrinology specialist, mostly to give weight, were performed CFR with echocardiography before and 3 months after the treatment.

Diabetic patients

Diabetic patients, who were planned to start semaglutide by an endocrinology specialist and were otherwise has same demographic data as non-diabetic patients, were performed CFR with echocardiography before and 3 months after the treatment

Eligibility Criteria

• Age: 28 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients who were diabetic and non-diabetic and planned to start semaglutide has referred to cardiology clinic for the study.

You may qualify if:

• Patients who were planned to start semaglutide.

You may not qualify if:

• Ischemic heart disease
• Previous stent implantation or coronary bypass
• Heart failure
• Cardiomyopathies
• Inflammatory diseases
• Autoimmune rheumatic disease
• Chronic liver and renal insufficiency

Sponsors & Collaborators

• Ekrem Bilal Karaayvaz: lead
• MEDICANA: collaborator

Study Sites (1)

Medicana International Istanbul Hospital

Istanbul, 34520, Turkey (Türkiye)

Location

Related Publications (2)

• Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsboll T; SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016 Nov 10;375(19):1834-1844. doi: 10.1056/NEJMoa1607141. Epub 2016 Sep 15.

  PMID: 27633186 BACKGROUND

• Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornoe CW, Ryan DH; SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11.

  PMID: 37952131 BACKGROUND

MeSH Terms

Conditions

Obesity; Overweight; Diabetes Mellitus

Condition Hierarchy (Ancestors)

Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Assistant Professor

Study Record Dates

• First Submitted: September 17, 2025
• First Posted: September 24, 2025
• Study Start: January 7, 2025
• Primary Completion: August 1, 2025
• Study Completion: August 1, 2025
• Last Updated: September 24, 2025

Record last verified: 2025-09

Locations

TU (1)